Yukiko Takayama

Dr. Yukiko Takayama

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2024 in Pancreatology
Verified
Journal Article
Open access
TOTakao Ohtsuka
Takao Ohtsuka
HMHiroyuki Maguchi
Hiroyuki Maguchi
STShoji Tokunaga
Shoji Tokunaga
SHSusumu Hijioka
Susumu Hijioka
YTYukiko Takayama
Yukiko Takayama
MTMasao Tanaka
Masao Tanaka
The natural history of branch-duct intraductal papillary mucinous cystic neoplasms (BD-IPMNs) in the pancreas remains unclear. This study aimed to answer this clinical question by focusing on the development of concomitant pancreatic ductal adenocarcinomas (cPDAC). The Japan Pancreas Society conducted a prospective multicenter surveillance study of BD-IPMN every six months for five years. The primary endpoints were progression of BD-IPMN, progression to high-grade dysplasia/invasive carcinoma (HGD/IC), and cPDAC. Factors predicting the progression of BD-IPMN to HGD/IC and development of cPDAC were also assessed as secondary endpoints. Among the 2104 non-operated patients, 348 (16.5 %) showed progression of primary BD-IPMN. Cumulative incidences of BD-IPMN with HGD/IC and cPDAC during the 5.17-year surveillance period were 1.90 % and 2.11 %, respectively, and standard incidence ratios of BD-IPMN with HGD/IC and cPDAC were 5.28 and 5.73, respectively. Of 38 cPDACs diagnosed during surveillance, 25 (65.8 %) were resectable. The significant predictive characteristics of BD-IPMN for progression to HGD/IC were larger cyst size (p = 0.03), larger main pancreatic duct size (p < 0.01), and mural nodules (p = 0.02). Significant predictive characteristics for the development of cPDAC were male sex (p = 0.03) and older age (p = 0.02), while the size of IPMN was not significant. Careful attention should be given to "dual carcinogenesis" during BD-IPMN surveillance, indicating the progression of BD-IPMN to HGD/IC and development of cPDAC distinct from BD-IPMN, although the establishment of risk factors that predict cPDAC development remains a challenge (UMIN000007349).

24 May 2025 in Cancers
Verified
Journal Article
Open access
PDF file
NONao Otsuka
Nao Otsuka
YSYutaka Shimamatsu
Yutaka Shimamatsu
RHRyunosuke Hakuta
Ryunosuke Hakuta
YTYukiko Takayama
Yukiko Takayama
YNYousuke Nakai
Yousuke Nakai
With the increasing use of imaging modalities such as ultrasonography, computed tomography, and magnetic resonance imaging, incidental findings of pancreatic abnormalities, including pancreatic cysts and fatty pancreas (FP), have become more common. FP, also referred to as pancreatic steatosis, intra-pancreatic fat deposition, or fatty pancreas disease, is characterized by the accumulation of fat in the pancreas. Although FP has been associated with metabolic syndromes such as obesity and diabetes, its clinical significance remains unclear. Recent evidence suggests that FP may play a role in pancreatic carcinogenesis. Metabolic disorders, including obesity, insulin resistance, and diabetes, have been implicated in the development of FP. Additionally, FP has been linked to an increased risk of pancreatic ductal adenocarcinoma (PDAC), possibly due to chronic inflammation, lipotoxicity, and an altered pancreatic microenvironment. While early detection of PDAC remains challenging, surveillance strategies for high-risk individuals, such as those with pancreatic cysts, new-onset diabetes, or a genetic predisposition, may be crucial. In this context, FP may be incorporated into this surveillance of high-risk individuals. Some pharmacological interventions, including glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors, have shown potential in reducing pancreatic fat accumulation, although further studies are needed to confirm their efficacy.

30 January 2026 in Clinical Endoscopy
Verified
Journal Article
Open access
YNYousuke Nakai
Yousuke Nakai
RHRyunosuke Hakuta
Ryunosuke Hakuta
YSYutaka Shimamatsu
Yutaka Shimamatsu
NONao Otsuka
Nao Otsuka
YTYukiko Takayama
Yukiko Takayama
Diagnosis of biliary strictures remains challenging because of the low sensitivity of conventional transpapillary sampling using endoscopic retrograde cholangiopancreatography. New devices and tips have been developed to increase the diagnostic yield of conventional transpapillary sampling. However, additional endoscopic procedures are often necessary for indeterminate biliary strictures. Two major approaches for indeterminate biliary strictures are endoscopic ultrasonography-guided sampling and peroral cholangioscopy (POCS)-guided biopsy. The selection of modalities should be considered based on the stricture location. Although endoscopic ultrasound is the preferred approach for distal biliary strictures, POCS is preferred for perihilar biliary strictures. Endoscopic ultrasonography-guided sampling is highly sensitive in cases with a mass, but the sensitivity of POCS-guided biopsies is unsatisfactory, and discrepancy with the visual diagnosis of POCS is common. Whether these advanced techniques should be performed as the initial procedure or as a rescue after a failed diagnosis by conventional transpapillary sampling needs to be clarified in terms of diagnostic yield and cost-effectiveness.

10 February 2025 in Pancreatology
Verified
Journal Article
Open access
TSTaro Shibuki
Taro Shibuki
MIMasafumi Ikeda
Masafumi Ikeda
MYMasayuki Yokoyama
Masayuki Yokoyama
YSYusuke Sano
Yusuke Sano
Junji FuruseJunji Furuse
Junji Furuse
MUMakoto Ueno
Makoto Ueno
Depth of response (DpR; maximum % reduction from baseline in sum of the target lesion diameters) has demonstrated potential in predicting prognosis in several malignancies. However, its role in locally advanced pancreatic cancer (LAPC) is still unclear. In JCOG1407, modified FOLFIRINOX (mFOLFIRINOX) and gemcitabine plus nab-paclitaxel (GnP) exhibited comparable efficacy for LAPC. In this exploratory analysis using the data of JCOG1407, we focused on the association between DpR and prognosis. DpR was classified into three groups at the tertile point and patients' backgrounds and survival were compared. The impact of DpR on survival outcomes was evaluated using the multivariable Cox proportional hazard model. Of the 126 patients enrolled in JCOG1407, 109 patients were included, categorized into three DpR groups: T1 (<-37.2 %), T2 (-37.2 to -13.6 %), and T3 (>-13.6 %). The median DpR was significantly greater in the GnP arm than in the mFOLFIRINOX arm (-28.9 vs. -22.7 %, P = 0.041). Median duration of response tended to be shorter in the GnP arm than in the mFOLFIRINOX arm, although the difference was not significant (5.3 vs. 8.2 months, P = 0.132). Greater DpR (T1) had a significantly larger impact on better progression-free survival (PFS) and overall survival (OS) than T3, with the hazard ratio of 0.469 (95 % confidence interval [CI] 0.268-0.821, P = 0.008), and 0.398 (95 % CI 0.217-0.728, P = 0.003), respectively. mFOLFIRINOX and GnP had similar OS, it is noteworthy that the regimens exhibited differences in DpR, with GnP leading to greater DpR. Greater DpR are associated with improved survival in patients with LAPC.

22 August 2026 in Pancreatology
Verified
Journal Article
Closed access
YKYusuke Kawamoto
Yusuke Kawamoto
GHGoro Honda
Goro Honda
MKMasataka Kikuyama
Masataka Kikuyama
YTYukiko Takayama
Yukiko Takayama
SSSatomi Saito
Satomi Saito
YNYousuke Nakai
Yousuke Nakai

30 October 2025 in The Korean Journal of Pancreas and Biliary Tract
Verified
Journal Article
Open access
PDF file
YNYousuke Nakai
Yousuke Nakai
RHRyunosuke Hakuta
Ryunosuke Hakuta
RNRyota Nakabayashi
Ryota Nakabayashi
YSYutaka Shimamatsu
Yutaka Shimamatsu
NONao Otsuka
Nao Otsuka
YTYukiko Takayama
Yukiko Takayama
Endoscopic ultrasound-guided biliary drainage (EUS-BD) has emerged as an important alternative to transpapillary biliary drainage by endoscopic retrograde cholangiopancreatography (ERCP) for malignant biliary obstruction (MBO), especially in cases with failed ERCP. Given the increasing evidences of safety and effectiveness of EUS-BD, EUS-BD as primary biliary drainage has been investigated in clinical trials. However, there are still obstacles that need to be addressed prior to clinical application. In this narrative review, clinical outcomes, hurdles and future perspectives of primary EUS-BD for MBO are discussed.